PDS Biotechnology Corporation

183 articles with PDS Biotechnology Corporation

• PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101

  6/2/2022

  PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA ® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.

• PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into EuropePromising preliminary clinical results validate expansion of study initially into the United Kingdom

  5/31/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™ T-cell activating technologies, announced the acceptance of its Clinical Trial Application (CTA) from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.

• PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022

  5/26/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced an upcoming poster presentation of preliminary data from its ongoing Phase 2 VERSATILE-002 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting.

• PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022

  5/26/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), today announced an upcoming poster discussion presentation of clinical data from the ongoing Phase 2 triple combination trial led by the National Cancer Institute (NCI), of the National Institutes of Health (NIH), at the American Society of Clinical Oncology (ASCO) Annual Meeting.

• PDS Biotechnology to Host Conference Call Following Poster Presentations of PDS0101 Data at 2022 ASCO Annual Meeting Conference Call on Tuesday, June 7, 2022 at 8:00 AM EDT

  5/25/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced its management team will host a conference call following two poster presentations of PDS0101 data at 2022 American Society of Clinical Oncology Meeting (ASCO).

• PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development

  5/18/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that Sanjay Zaveri has joined PDS Biotech as Senior Vice President, Business Development.

• PDS Biotech to Participate at Upcoming Investor Conferences

  5/17/2022

  PDS Biotechnology Corporation announced that its management will present at the H.C. Wainwright Global Investment Conference and the LD Micro Invitational and will participate at the UBS Healthcare Virtual One-on-One Day.

• PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial ResultsCompany to host conference call and webcast today, May 11, 2022, at 8:00 AM EDT

  5/11/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™ T-cell activating technologies, will discuss its financial results for the quarter ended March 31, 2022, and provide a business update on its conference call today.

• PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results

  4/28/2022

  PDS Biotechnology Corporation today announced that the Company will release financial results for the first quarter of 2022 on Wednesday, May 11, 2022, before the market opens.

• PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

  4/27/2022

  PDS Biotechnology Corporation announced the titles of two abstracts accepted for poster presentations during the 2022 American Society of Clinical Oncology Annual Meeting being held from June 3-7, 2022.

• PDS Biotech Chief Medical Officer, Lauren V. Wood, to Chair Session at the World Vaccine Congress

  4/20/2022

  PDS Biotechnology Corporation today announced Lauren V. Wood, M.D. will be chairing Day 2 of the Cancer and Immunotherapy Vaccines Conference at the World Vaccine Congress being held in Washington, DC.

• PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

  4/19/2022

  PDS Biotechnology Corporation announced that on April 18, 2022, the Company received $1.2 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program for State Fiscal Year 2021.

• PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 08, 2022

  4/8/2022

  PDS Biotechnology Corporation announced that on April 6, 2022 PDS Biotech granted nonstatutory stock options to Robert Imani, M.D., PhD, PDS Biotech’s Vice President Medical Director to purchase 70,000 shares of PDS Biotech common stock.

• PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results

  3/31/2022

  PDS Biotechnology Corporation provided a business update and announced its financial results for the year ended December 31, 2021.

• PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call

  3/22/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that it has changed the date of its previously announced 2021 fourth quarter and full year earnings release call from Wednesday, March 23, 2022 to 8:00 AM EDT on Thursday, March 31, 2022.

• PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers

  3/15/2022

  PDS Biotechnology Corporation today announced that the National Cancer Institute (NCI) has achieved the intended enrollment objective of 30 patients in the checkpoint inhibitor (CPI).

• PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results

  3/9/2022

  PDS Biotechnology Corporation announced the Company will release financial results for the three- and twelve-month periods ended December 31, 2021, on Wednesday, March 23, 2022, before the market opens.

• PDS Biotechnology to Present at the 32nd Oppenheimer Annual Healthcare Conference

  3/1/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that its management will present at the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 15, 2022.

• PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

  2/24/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology, today announced the presentation of preliminary safety data.

• PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

  2/15/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced the initiation of an Investigator-Initiated Trial (ITT), MC200710, for PDS0101 alone or in combination with the checkpoint inhibitor, KEYTRUDA®.